Skip to content

April - Mathieu Bourgey, Maria Virginia Ruiz Cuevas

Event Details

Date/Time:

Wednesday, April 14th, 2021 16h30

Location:

Location: Online (Jitsi / YouTube Live)

headshot

Speaker: Mathieu Bourgey

Affiliation: Bioinformatics manager, Canadian Centre for Computational Genomics (C3G)

Talk Title: Insights into single cell sequencing analysis (in French)

Abstract:

Mathieu, Bioinformatics manager at the Canadian Centre for Computational Genomics (C3G), will give an overview of the technical aspects of single cell sequencing data analysis.

headshot

Speaker: Maria Virginia Ruiz Cuevas

Talk Title: Most Non-canonical Proteins Uniquely Populate the Proteome or Immunopeptidome

Abstract:

Maria Virginia will present how she uses sequencing data to identify, characterize and quantify non-canonical proteins found in cancer cells. These proteins possessing distinct characteristics could make a critical contribution to tumor immunosurveillance.

Significant evidence demonstrates the presence of unusual non-canonical proteins in cancer cells that appear to possess properties distinct from those of canonical proteins, making them important sources for the development of immunotherapies. Indeed, the immune system collects information about the health status of cells by reading protein fragments exposed on the cell surface. These fragments allow T cells to detect and eliminate cancer cells by reacting to the presence of unusual fragments. Because of their central role in cancer elimination, the identification of cancer-specific fragments is crucial for the design of vaccines that effectively stimulate the patient’s own immune system to fight the disease. My research therefore aims to elucidate the hitherto elusive rules of biogenesis of non-canonical proteins in cancer cells. To do so, I develop and use computational strategies to study sequencing data to identify, characterize and quantify these unusual proteins. This will provide novel information on the cellular processes of protein synthesis and folding in normal and cancer cells, and thus allow us to identify with high confidence cancer-specific actionable fragments that can be tested in therapeutic vaccines. 10.1016/j.celrep.2021.108815

Links: